Streetbeat News

APRE

Aprea Therapeutics, Inc.

https://atrinpharma.com

Industry

Biotechnology

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Open

3.28

Mkt cap

18M

Volume

16K

High

3.45

P/E Ratio

-1.16

52-wk high

8.85

Low

3.06

Div yield

N/A

52-wk low

2.15

Aprea Therapeutics announced it will host a virtual Key Opinion Leader (KOL) event focused on its drug candidate APR-1051.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 12:11 pm

HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target, as stated by analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 2:43 pm

Aprea Therapeutics has dosed the first patient in its Phase 1 ACESOT-1051 study of the oral WEE1 inhibitor APR-1051 as a monotherapy for advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:34 pm

Aprea Therapeutics' Safety Review Committee has endorsed dosing patients with ATRN-119 in the ABOYA-119 clinical trial. ATRN-119, a macrocyclic ATR inhibitor, has shown safety and tolerance through the first 5 cohorts with no dose-limiting toxicities. The company is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:48 pm

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintains a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 3:15 pm

Aprea Therapeutics reported Q1 EPS of $(0.67), surpassing the $(0.78) estimate, marking a 50% improvement from last year's $(1.34) per share loss. Sales reached $380.57K.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:47 pm

Aprea Therapeutics announced presentations on APR-1051 and ATRN-119 at AACR Annual Meeting 2024, highlighting pre-clinical and clinical updates. APR-1051, a WEE1 kinase inhibitor, shows potential for treating Cyclin E-overexpressing cancers with minimal off-target effects and low cardiotoxicity. ATRN-119, an ATR inhibitor, demonstrated safety and preliminary clinical benefit in an ongoing study. The company plans to initiate a Phase 1 trial for APR-1051 in June 2024.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 4:02 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings led the gainers with an 85.5% increase, while Telesis Bio experienced the largest drop among the losers, falling 11.8%. Other notable movers include Candel Therapeutics and Achilles Therapeutics, with the former rising 27.97% and the latter declining by 10% following its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 12:09 pm

Wedbush analyst Robert Driscoll maintains an Outperform rating on Aprea Therapeutics (NASDAQ:APRE) and raises the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:54 am

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Aprea Therapeutics (NASDAQ:APRE) with a maintained price target of $20.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 3:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.